The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for progression of disease. There is opportunity to gain more information about the utility of Vectra in a real-world clinical setting. This study will, therefore, evaluate the utility of Vectra for guiding treatment decisions and improving RA-related outcomes in comparison with usual care, which will not include Vectra testing. This study will enable a direct evaluation of the clinical benefit associated with using Vectra to guide treatment decisions in patients with RA.
Rheumatoid Arthritis (RA)
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for progression of disease. There is opportunity to gain more information about the utility of Vectra in a real-world clinical setting. This study will, therefore, evaluate the utility of Vectra for guiding treatment decisions and improving RA-related outcomes in comparison with usual care, which will not include Vectra testing. This study will enable a direct evaluation of the clinical benefit associated with using Vectra to guide treatment decisions in patients with RA.
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
-
Bio Solutions Clinical Research, La Mesa, California, United States, 91942
Brigid Freyne, MD, Murrieta, California, United States, 92563
J. Lee MD Medical Corp, Orange, California, United States, 92868
Delaware Arthritis, Lewes, Delaware, United States, 19958
AARDS Research, Inc., Aventura, Florida, United States, 33180
Robert W. Levin, MD, PA, Clearwater, Florida, United States, 33765
Artemisa Analytics, Miami, Florida, United States, 33133
Rheumatology Associates of Central Florida, P.A., Orlando, Florida, United States, 32806
Clin-Med Research & Development, LLC, South Miami, Florida, United States, 33141
Accurate Clinical Research, Lake Charles, Louisiana, United States, 70605
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Sequenom, Inc.,
Elena Hitraya, MD, STUDY_DIRECTOR, Consultant
Jeffrey R. Curtis, MD, MPH, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham
2025-09-15